PMID- 26109675
OWN - NLM
STAT- MEDLINE
DCOM- 20151201
LR  - 20181113
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 212 Suppl 2
IP  - Suppl 2
DP  - 2015 Oct 1
TI  - Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus 
      Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
PG  - S443-51
LID - 10.1093/infdis/jiv316 [doi]
AB  - Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing 
      Ebolavirus glycoproteins (GPs) in place of the VSV G protein demonstrated 
      protection of nonhuman primates from lethal homologous Ebolavirus challenge. 
      Those pseudotype vectors contained no additional attenuating mutations in the 
      rVSV genome. Here we describe rVSV vectors containing a full complement of VSV 
      genes and expressing the Ebola virus (EBOV) GP from an additional transcription 
      unit. These rVSV vectors contain the same combination of attenuating mutations 
      used previously in the clinical development pathway of an rVSV/human 
      immunodeficiency virus type 1 vaccine. One of these rVSV vectors (N4CT1-EBOVGP1), 
      which expresses membrane-anchored EBOV GP from the first position in the genome 
      (GP1), elicited a balanced cellular and humoral GP-specific immune response in 
      mice. Guinea pigs immunized with a single dose of this vector were protected from 
      any signs of disease following lethal EBOV challenge, while control animals died 
      in 7-9 days. Subsequently, N4CT1-EBOVGP1 demonstrated complete, single-dose 
      protection of 2 macaques following lethal EBOV challenge. A single 
      sham-vaccinated macaque died from disease due to EBOV infection. These results 
      demonstrate that highly attenuated rVSV vectors expressing EBOV GP may provide 
      safer alternatives to current EBOV vaccines.
CI  - (c) The Author 2015. Published by Oxford University Press on behalf of the 
      Infectious Diseases Society of America. All rights reserved. For Permissions, 
      please e-mail: journals.permissions@oup.com.
FAU - Matassov, Demetrius
AU  - Matassov D
AD  - Department of Virology and Vaccine Vectors.
FAU - Marzi, Andrea
AU  - Marzi A
AD  - Laboratory of Virology.
FAU - Latham, Terri
AU  - Latham T
AD  - Department of Virology and Vaccine Vectors.
FAU - Xu, Rong
AU  - Xu R
AD  - Department of Immunology, Profectus BioSciences, Tarrytown, New York.
FAU - Ota-Setlik, Ayuko
AU  - Ota-Setlik A
AD  - Department of Immunology, Profectus BioSciences, Tarrytown, New York.
FAU - Feldmann, Friederike
AU  - Feldmann F
AD  - Rocky Mountain Veterinary Branch, Rocky Mountain Laboratories, Division of 
      Intramural Research, National Institute of Allergy and Infectious Diseases, 
      National Institutes of Health, Hamilton, Montana.
FAU - Geisbert, Joan B
AU  - Geisbert JB
AD  - Galveston National Laboratory Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston.
FAU - Mire, Chad E
AU  - Mire CE
AD  - Galveston National Laboratory Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston.
FAU - Hamm, Stefan
AU  - Hamm S
AD  - Department of Virology and Vaccine Vectors.
FAU - Nowak, Becky
AU  - Nowak B
AD  - Department of Virology and Vaccine Vectors.
FAU - Egan, Michael A
AU  - Egan MA
AD  - Department of Immunology, Profectus BioSciences, Tarrytown, New York.
FAU - Geisbert, Thomas W
AU  - Geisbert TW
AD  - Galveston National Laboratory Department of Microbiology and Immunology, 
      University of Texas Medical Branch, Galveston.
FAU - Eldridge, John H
AU  - Eldridge JH
AD  - Department of Virology and Vaccine Vectors Department of Immunology, Profectus 
      BioSciences, Tarrytown, New York.
FAU - Feldmann, Heinz
AU  - Feldmann H
AD  - Laboratory of Virology.
FAU - Clarke, David K
AU  - Clarke DK
AD  - Department of Virology and Vaccine Vectors.
LA  - eng
GR  - R01 AI098817/AI/NIAID NIH HHS/United States
GR  - U19 AI109711/AI/NIAID NIH HHS/United States
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20150624
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antibodies, Viral)
RN  - 0 (Glycoproteins)
RN  - 0 (Vaccines, Attenuated)
RN  - 0 (Viral Proteins)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/immunology
MH  - Ebolavirus/*immunology
MH  - Female
MH  - Genetic Vectors/genetics/*immunology
MH  - Glycoproteins/genetics/immunology
MH  - Guinea Pigs
MH  - Hemorrhagic Fever, Ebola/*immunology/virology
MH  - Immunity, Cellular/immunology
MH  - Immunity, Humoral/immunology
MH  - Macaca mulatta
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Vaccination/methods
MH  - Vaccines, Attenuated/*immunology
MH  - Vesicular Stomatitis/immunology
MH  - Vesiculovirus/immunology
MH  - Viral Proteins/immunology
MH  - Viral Vaccines/*immunology
PMC - PMC4564554
OTO - NOTNLM
OT  - Ebola vaccine
OT  - attenuation
OT  - challenge
OT  - glycoprotein
OT  - nonhuman primates
OT  - rVSV vector
EDAT- 2015/06/26 06:00
MHDA- 2015/12/15 06:00
PMCR- 2015/09/01
CRDT- 2015/06/26 06:00
PHST- 2015/06/26 06:00 [entrez]
PHST- 2015/06/26 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
AID - jiv316 [pii]
AID - 10.1093/infdis/jiv316 [doi]
PST - ppublish
SO  - J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S443-51. doi: 
      10.1093/infdis/jiv316. Epub 2015 Jun 24.